A mid-sized multinational biopharmaceutical company developing transformative therapies for rare diseases crafted a launch price strategy across 6 countries for a second oncology indication with Indegene's support. The strategy encompassed gross/net pricing approaches and a roadmap factoring key pharmaceutical elements. Indegene's advanced software analyzed primary market research from 25 pharmacy directors, 25 physicians covering 209 million US lives, and 10 EU5 payers, modeling multi-country pricing scenarios with predictive analytics. This optimized launch economics, aligned stakeholder insights, and accelerated market-ready pricing decisions.

Join for free to read